Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms
Open Access
- 8 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-15
- https://doi.org/10.1038/s41467-020-16128-5
Abstract
Bruton's tyrosine kinase (Btk) is critical for B-cell maturation and activation. Btk loss-of-function mutations cause human X-linked agammaglobulinemia (XLA). In contrast, Btk signaling sustains growth of several B-cell neoplasms which may be treated with tyrosine kinase inhibitors (TKIs). Here, we uncovered the structural mechanism by which certain XLA mutations in the SH2 domain strongly perturb Btk activation. Using a combination of molecular dynamics (MD) simulations and small-angle X-ray scattering (SAXS), we discovered an allosteric interface between the SH2 and kinase domain required for Btk activation and to which multiple XLA mutations map. As allosteric interactions provide unique targeting opportunities, we developed an engineered repebody protein binding to the SH2 domain and able to disrupt the SH2-kinase interaction. The repebody prevents activation of wild-type and TKI-resistant Btk, inhibiting Btk-dependent signaling and proliferation of malignant B-cells. Therefore, the SH2-kinase interface is critical for Btk activation and a targetable site for allosteric inhibition. Constitutive Btk signaling drives several B-cell cancers. Here the authors demonstrate key allosteric intramolecular interactions between the SH2 domain and the kinase domain of Btk, and propose an alternative approach for inhibition of both wild-type and tyrosine kinase inhibitor-resistant Btk.This publication has 57 references indexed in Scilit:
- Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineeringProceedings of the National Academy of Sciences of the United States of America, 2012
- Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits LeukemogenesisCell, 2011
- A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domainNature Structural & Molecular Biology, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- SH2-Dependent Autophosphorylation within the Tec Family Kinase ItkJournal of Molecular Biology, 2009
- DAMMIF, a program for rapidab-initioshape determination in small-angle scatteringJournal of Applied Crystallography, 2009
- Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase ActivationCell, 2008
- The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProceedings of the National Academy of Sciences of the United States of America, 2007
- Canonical sampling through velocity rescalingThe Journal of Chemical Physics, 2007
- PRIMUS: a Windows PC-based system for small-angle scattering data analysisJournal of Applied Crystallography, 2003